Predictive Oncology (POAI) - 2025 Q3 - Quarterly Results

Financial Performance - Revenue for Q3 2025 was $3,618, slightly down from $3,907 in Q3 2024, indicating minimal change year-over-year[9] - Basic and diluted loss per common share from continuing operations for Q3 2025 was $(107.24), compared to $(4.99) for Q3 2024[9] - The net loss for the company was $82,165,178, compared to a net loss of $10,494,794 in the prior period[18] - Loss from continuing operations was $77,646,737, significantly higher than the loss of $2,129,880 reported previously[18] - Loss per common share, basic and diluted, was $136.12, compared to $31.20 in the previous period[18] - The company reported a total operating loss of $8,226,779, compared to $8,207,133 in the prior period[18] Expenses - General and administrative expenses increased by $1.1 million to $2.6 million in Q3 2025, primarily due to higher legal fees and stock-based compensation[9] - Total operating expenses for the period were $8,271,694, a slight increase from $8,235,685 in the previous period[18] - General and administrative expenses amounted to $6,316,930, up from $5,696,109 in the previous period[18] - Research and development expenses were $1,548,678, a decrease from $1,724,013 in the prior period[18] - Sales and marketing expenses increased to $406,086 from $815,563 in the previous period[18] - Sales and marketing expenses increased to $133,494 in Q3 2025 from $72,667 in Q3 2024, attributed to higher digital marketing consultant fees[9] Digital Asset Strategy - The company recorded a derivative liability of $74.4 million related to the initiation of its digital asset treasury strategy focused on the ATH token[9] - The company initiated a digital asset treasury strategy focused on ATH, receiving approximately $50.8 million in cash gross proceeds and in-kind contributions valued at approximately $292.7 million[4] - The company held approximately 5.70 billion ATH with a market value of approximately $152.8 million as of November 10, 2025[4] - The company experienced a significant loss on derivative instruments amounting to $74,366,000[18] Corporate Developments - The company appointed Shawn Matthews, CEO of DNA Holdings, to its Board of Directors[4] - The company announced a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing to improve patient outcomes[4]